TLR9 and autoimmune disease: CpG 52364 is a small molecule TLR antagonist specifically developed for TLR7, TLR8, and TLR9 to inhibit progression of SLE and other autoimmune diseases at an early stage by blocking inappropriate TLR activation [140].